Beyond Portola Pharmaceuticals' Disappointing Data
Trial results for its anticoagulant Betrixaban were a mixed bag, but it could still find its way to market and if not, another drug with a FDA approval date in August could still move the needle at Portola Pharmaceuticals.
This podcast was recorded on Mar. 30, 2016.